Supernus Pharmaceuticals Inc (SUPN): Padmanabh P. Bhatt , Sr. VP of IP, CSO of Supernus Pharmaceuticals Inc sold 30,762 shares on Apr 11, 2016. The Insider selling transaction was disclosed on Apr 12, 2016 to the Securities and Exchange Commission. The shares were sold at $16.49 per share for a total value of $507,228.47.
Company has been under the radar of several Street Analysts.Supernus Pharmaceuticals Inc is Upgraded by Jefferies to Buy. Earlier the firm had a rating of Hold on the company shares. The Rating was issued on Feb 8, 2016.
Currently the company Insiders own 27.7% of Supernus Pharmaceuticals Inc shares according to the proxy statements.Institutional Investors own 90.88% of Supernus Pharmaceuticals Inc shares.During last six month period, the net percent change held by insiders has seen a change of -17.93%.
Shares of Supernus Pharmaceuticals Inc (SUPN) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -0.17 points or -1.02% at $16.55 with 5,46,255 shares getting traded. Post opening the session at $16.88, the shares hit an intraday low of $16.19 and an intraday high of $16.9311 and the price vacillated in this range throughout the day. The company has a market cap of $818 M and the number of outstanding shares has been calculated to be 4,94,00,473 shares. The 52-week high of Supernus Pharmaceuticals Inc is $23.3008 and the 52-week low is $9.5101.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD) autism and bipolar disorder) and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR Trokendi XR SPN-810 SPN-812 and SPN-809.